Study on Predicting Liver Cancer and Transplant Needs in Adults with Metabolic Liver Disease MASLDMASH

What this Trial Is About

Researchers are conducting the BOMASH study, a single-center observational research project focusing on patients with Metabolic-Associated Steatotic Liver Disease MASLD and Metabolic-Associated Steatohepatitis MASH. The study aims to identify predictive factors and biomarkers that can help determine the risk of developing liver complications, including hepatocellular carcinoma HCC and the need for liver transplantation. This study includes both newly diagnosed patients and those already under follow-up or routine care at the center. The study does not involve any pharmacological treatments and includes two groups of MASLDMASH patients those prospectively enrolled and those retrospectively enrolled. It relies on collecting data through routine diagnostic and therapeutic care, including the use of non-invasive tests and liver biopsies when clinically indicated. The research hopes to use this data to improve risk stratification and support targeted management for patients at higher risk of severe liver disease. Participants will be monitored over a long period, from enrollment until November 2044, with regular data collection on outcomes such as the number and timing of HCC cases and liver transplants. Researchers will also track responses to diet and pharmacological therapies, biochemical changes, and the progression of liver complications. This comprehensive follow-up aims to provide valuable prognostic information to improve care planning and healthcare sustainability for metabolic liver disease patients.

Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH